Skip to content

Evolus EOLS Common stock, shares issued (in shares)

Common stock, shares issued (in shares) at other companies

AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$73.1M+6.7%
Gross profit$48.9M+4.8%
Operating income-$6.8M+54.9%
Net income-$10.7M+43.5%
EPS (diluted)-$0.16+46.7%

Balance sheet

See full
Cash & equivalents$49.8M-26.7%
Total debt$164.9M-4.1%
Total equity-$28.8M-336%
Total assets$220.6M+3.4%

Cash flow

See full
Operating cash flow-$10.0M+36.3%
CapEx$415.0K+30.1%
Free cash flow-$10.4M+35.0%

Valuation

See full
Market cap$470.86M-21.3%
Enterprise value$585.97M-16.6%
P/S1.6×-0.6×

Profitability

See full
Gross margin66.1%-2.4pp
Operating margin-13.7%-1.9pp
Net margin-14.4%-3.3pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio-0.3×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's common stock, shares issued (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolus's common stock, shares issued (in shares)?
Evolus (EOLS) reported common stock, shares issued (in shares) of $65.84M in Q1 2026.
How has Evolus's common stock, shares issued (in shares) changed year-over-year?
Evolus's common stock, shares issued (in shares) increased by 2.2% year-over-year, from $64.45M to $65.84M.
What is the long-term trend for Evolus's common stock, shares issued (in shares)?
Over 5 years (2020 to 2025), Evolus's common stock, shares issued (in shares) has grown at a 14.0% compound annual growth rate (CAGR), from $33.75M to $65.01M.